Showing 2751-2760 of 3190 results for "".
- Kourtney Kardashian is Manuka Doctor's New Brand Ambassadorhttps://practicaldermatology.com/news/kourtney-kardashian-is-manuka-doctors-new-brand-ambassador/2458614/Kybella has Khloe, and now Manuka Doctors got Kourtney. Kourtney Kardashian is the new face of Manuka Doctor, a skincare line comprising Manuka Honey and patented Purified Bee Venom.
- American Telemedicine Association Names New Vice Chair of Teledermatologyhttps://practicaldermatology.com/news/american-telemedicine-association-names-new-vice-chair-of-teledermatology/2458616/Mark P. Seraly, MD, founder and chief medical officer of Iagnosis, a developer of telemedicine solutions and the creator of DermatologistOnCall, has been elected Vice Chair of the Teledermatology Special Interest Group of the American Telemedicine Association (ATA) the leading international resou
- Pfizer-AGN Deal Offhttps://practicaldermatology.com/news/all-eyes-on-pfizer-agn-deal-is-it-doa/2458617/UPDATE: Allergan and Pfizer have mutually agreed to end their merger agreement, according to a statement from Allergan. Pfizer has agreed to pay Allergan $150 million in reimbursement for expenses associated with the transaction. Dublin-based Allergan reiterates in the statement its growth opport
- New from Suneva: Regenica® Rejuvenating Dual Serumhttps://practicaldermatology.com/news/new-from-suneva-regenica-rejuvenating-dual-serum/2458620/Suneva Medical, Inc., is rolling out Regenica® Rejuvenating Dual Serum, the newest addition to the Regenica® skin care line. The dual chamber serum is created via growth factor
- Next Stop FDA Approval? Dupilumab Improves Symptoms in Moderate-to-Severe ADhttps://practicaldermatology.com/news/next-stop-fda-approval-dupilumab-improves-symptoms-in-moderate-to-severe-ad/2458625/Dupilumab helps improve the signs and symptoms of moderate-to-severe atopic dermatitis (AD) in adults, according to two late stage clinical trials. The U.S. Food and Drug Administration (FDA) granted dupilumab Breakthrough Therapy designation in AD in November 2014. U.S. regulatory
- Rosacea Awareness Month Highlights Potential Increased Health Riskshttps://practicaldermatology.com/news/rosacea-awareness-month-highlights-potential-increased-health-risks/2458624/New studies are now revealing potential associations between rosacea and increased risks of cardiovascular disease, gastrointestinal disease, certain types of cancer and many other systemic illnesses. The National Rosacea Society (NRS) has designated April as Rosacea Awareness Month to alert the
- Many Parents are Concerned About Fake Online MD Reviewshttps://practicaldermatology.com/news/many-parents-are-concerned-about-fake-online-md-reviews/2458637/More than two-thirds of parents believe some online doctor reviews are fake, while slightly fewer say there are not enough ratings to make a good decision, according a report from C.S. Mott Children’s Hospital National Poll on Children’s Health. More than half of p
- New System Depicts Skin Regeneration in Technicolorhttps://practicaldermatology.com/news/new-system-depicts-skin-regeneration-in-technicolor/2458638/Thanks to a genetically engineered line of technicolor zebrafish, researchers can now visualize skin regeneration at high resolution in real time. Many available methods rely on samples that are "snapshots" of cell growth and movement, but the new system, called Skinbow, c
- Study Links Psoriasis to Bone Loss. Is IL-17 to Blame?https://practicaldermatology.com/news/study-links-psoriasis-to-bone-loss-is-il-17-to-blame/2458641/Psoriasis is linked to widespread bone loss, according to Researchers from the Genes, Development and Disease Group at the Spanish National Cancer Research Centre (CNIO) in Madrid. The new study, which appears in Sc
- Vitae Achieves Proof-of-Concept with First-in-Class RORyt Inhibitor for Psoriasishttps://practicaldermatology.com/news/vitae-achieves-proof-of-concept-with-first-in-class-roryt-inhibitor-for-psoriasis/2458643/Vitae Pharmaceuticals, Inc. shared positive top-line results from its Phase 2a proof-of-concept clinical trial of VTP-43742 in psoriatic patients. VTP-43742 is Vitae's wholly owned, first-in-class, orally active RORγt inhibitor with the potential to transform the treatment of multiple a